Dermatology
333 Cedar Street, LCI 501
PO Box 208059
New Haven, CT 06520-8059
Tel: 203.785.4091
Fax: 203.785.7637
A clinical trial of Transimmunization for the treatment of solid cell tumors in stage IIIB or greater non-small cell lung cancer (NSCLC) is currently underway at Yale. Information about this trial is listed below.
For more information, please call the
Yale Cancer Center Clinical Trials Office at
203-785-5702.
Transimmunization was developed after years of laboratory research advanced the understanding of the underlying principles of ECP (Extracorporeal photochemotherapy or photopheresis). The scientific basis of ECP is the ability to stimulate the development of powerful stimulators of the immune system called dendritic cells. Transimmunization is a more efficient means by which to bring these dendritic cells in contact with target cancer cells, before they are retuned to the body to stimulate an anti-tumor immune response.
HIC Number |
26573 |
Full Title |
Phase I Feasibility Study: Combined Modality Treatment with Transimmunization for Non-Small Cell Lung Cancer |
Trial Type |
Therapeutic |
Disease |
Phase I |
PI |
Lynn Wilson |
Primary Objective |
To assess the safety of utilizing Transimmunization as a component of combined modality treatment of stage IIIB or greater non-small cell lung cancer (NSCLC). |
Target Population |
Histologically confirmed non-small cell lung cancer; Staging by CT scan of chest, abdomen and MRI of brain; Willing and able to undergo two lung biopsy procedures by bronchoscopy. |
Exclusion |
History of, or active infection with, human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; History of allergic reactions attributed to compounds of similar composition to 8 methoxypsoralen. |
FDA Phase |
I |
At Yale, there are hundreds of clinical research studies underway for a wide variety of conditions. There are also many trials that need healthy volunteers. Learn more...